XML 75 R64.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Commitments and Contingencies - Additional Information (Details) $ in Millions | 1 Months Ended | 2 Months Ended | 3 Months Ended |  |  |
--- | --- | --- | --- | --- | --- | ---
May 31, 2018 Patent | May 31, 2017 Patent | Dec. 31, 2016 USD ($) | Mar. 31, 2016 USD ($) | May 31, 2018 Patent | Jun. 30, 2016 USD ($) | Jun. 30, 2018 USD ($) | Feb. 28, 2018 Pending_Claim | Dec. 31, 2017 USD ($)
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |
Damages awarded |  |  | $ 2,540 |  |  |  |  |  |
Motion invalidated past damages, amount |  |  | $ 2,540 |  |  |  |  |  |
Damages awarded but dismissed |  |  |  | $ 200 |  |  |  |  |
Litigation accrual |  |  |  |  |  |  | $ 0 |  | $ 0
Number of pending claims with motions to dismiss | Pending_Claim |  |  |  |  |  |  |  | 2 |
Merck '499 and '712 patents |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |
Damages awarded but dismissed, value |  |  |  |  |  | $ 200 |  |  |
Amneal Pharmaceuticals, LLC V.S. Gilead Sciences, Inc |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |
Number of patents allegedly infringed | Patent |  | 2 |  |  |  |  |  |  |
Aurobindo Pharma USA Inc V.S. Gilead Sciences, Inc |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |
Number of patents allegedly infringed | Patent |  |  |  |  | 2 |  |  |  |
Strides Pharma, Inc V.S. Gilead Sciences, Inc - Emtricitabine Patent |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |
Number of patents allegedly infringed | Patent | 2 |  |  |  |  |  |  |  |
Strides Pharma, Inc V.S. Gilead Sciences, Inc - Emtricitabine And Tenofovir Patent |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |
Number of patents allegedly infringed | Patent |  |  |  |  | 4 |  |  |  |

X
- Definition Loss Contingency, Damages Awarded but Dismissed, Value + References No definition available. + Details
Name: | gild_LossContingencyDamagesAwardedbutDismissedValue
Namespace Prefix: | gild_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Loss Contingency, Motion Invalidated For Past Damages, Value + References No definition available. + Details
Name: | gild_LossContingencyMotionInvalidatedForPastDamagesValue
Namespace Prefix: | gild_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Loss Contingency, Pending Claims With Motions To Dismiss, Number + References No definition available. + Details
Name: | gild_LossContingencyPendingClaimsWithMotionsToDismissNumber
Namespace Prefix: | gild_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount awarded to other party in judgment or settlement of litigation. + References No definition available. + Details
Name: | us-gaap_LitigationSettlementAmountAwardedToOtherParty
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_LossContingenciesLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of loss contingency liability. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=82911808&loc=d3e14326-108349 + Details
Name: | us-gaap_LossContingencyAccrualAtCarryingValue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of damages awarded to the plaintiff in the legal matter. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 9 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=82911808&loc=d3e14557-108349 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=82911808&loc=d3e14435-108349 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=82911808&loc=d3e14326-108349 + Details
Name: | us-gaap_LossContingencyDamagesAwardedValue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Number of another entity's patents that the entity has allegedly infringed. + References No definition available. + Details
Name: | us-gaap_LossContingencyPatentsAllegedlyInfringedNumber
Namespace Prefix: | us-gaap_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_LitigationCaseAxis=gild_Merck499and712patentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=gild_AmnealPharmaceuticalsLLCV.S.GileadSciencesIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=gild_AurobindoPharmaUSAIncV.S.GileadSciencesIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=gild_StridesPharmaIncV.S.GileadSciencesIncEmtricitabinePatentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=gild_StridesPharmaIncV.S.GileadSciencesIncEmtricitabineAndTenofovirPatentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |